2Suppliers
1Customers
2Debt Items
0Related Chains

BioAtla, Inc. Suppliers

TickerNameConfidenceEvidence
BEONE BEONE 90% As consideration for this amendment, the Company agreed to pay BeOne mid-single digit royalties on sales worldwide
HIMALAYA-THERAPEUTICS-SEZC HIMALAYA-THERAPEUTICS-SEZC 80% the Company also entered into an agreement with Himalaya Therapeutics SEZC, a related party

BioAtla, Inc. Customers

TickerNameConfidenceEvidence
CONTEXT-THERAPEUTICS-INC CONTEXT-THERAPEUTICS-INC 95% Under the terms of the Context License Agreement, BioAtla granted Context an exclusive, worldwide license to develop, manufacture and commercialize two licensed antibodies

BioAtla, Inc. Debt Obligations

InstrumentDescriptionConfidenceEvidence
BCAB-DEBT-8089 Warrants outstanding: 59.5 90% xbrl warrant detail from xbrl 2026-03-31.
BCAB-DEBT Debt stack $6.1M 90% Market cache reports total debt of $6.1M.

BioAtla, Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for BioAtla, Inc..

BioAtla, Inc. Ownership

HolderNameConfidenceEvidence
BCAB-OWNER-ACORN-CAPITAL-ADVISORS-LLC ACORN CAPITAL ADVISORS, LLC 90% 13F overlay lists ACORN CAPITAL ADVISORS, LLC as top holder; 35 tracked holders.

BioAtla, Inc. Extended Supply Chain Network

No secondary connectionsNo correlated companies found through shared supply chain relationships.